For patient support programs
Support patients from enrolment to the next dose.
Give patients a way to enrol, book training, receive reminders and reach the program’s nurses. Cater connects the app and website to your case-management system, under the program’s name.
From enrolment to ongoing support
See enrolment and a flagged message
Solvara Support Fictional A fictional program for a fictional therapy. The patient completes enrolment, books a first-dose appointment and later mentions a side effect in a message. “See what the program sees” opens the flagged message and report sent to drug safety. A separate manufacturer view contains program-level counts.
Try it in your browser
The app runs in your browser and saves your progress on this device. This is our real app for a demo organization. You experience what patients and staff see.
Enrol as a patient, then see what the program sees
Solvara SupportStep 1 of 2Before you join
Your doctor has prescribed your treatment. The program helps you start it and stay in touch with a nurse. It’s free, and funded by Arvenna Pharma (fictional).
What we collect
Your name, date of birth, contact details and language, your appointments, what you tell the program team, and the clinic that prescribed your treatment.
Who sees it
The program’s nurses and coordinators. Arvenna Pharma sees only totals, never your name, your messages or your doctor.
If you mention a side effect
The program team must pass it to Arvenna Pharma’s drug safety team, as Canadian rules require, with only what they need to assess it.
Stopping
Leave at any time in Profile, or call (416) 555-0137. Your care with your doctor doesn’t change.
I agree to join Solvara SupportText me remindersOptional. You can change this later.Agree and continue- Solvara Support
Book injection training
Your first dose, with a program nurse · about 45 minutes
At homeAt a clinicWed14FullThu152 timesFri163 timesMon193 timesThursday, October 15
10:00 a.m.2:30 p.m.No charge. The program covers this visit.
At your home in Toronto. The nurse brings what’s needed.
Book Thursday at 10:00 a.m.You can change or cancel up to 24 hours before.
- Program team
Thu, Oct 15
Grace Liu, program nurse · 4:10 p.m.
It was good to meet you today, Daniel. Message me any time if you have questions about your injections.
Wed, Oct 21
You · 9:14 a.m.
It went fine, thanks. Since Tuesday there’s a red, itchy rash where I injected. Is that normal?
Automatic reply
Thanks, Daniel. A program nurse will reply today; nurses answer from 8 a.m. to 8 p.m. Eastern. If you have trouble breathing, or swelling of your face, lips or throat, call 911.
Message the program teamSendIn an emergency, call 911.
- Solvara SupportSolvara SupportGLGrace LiuProgram nurse
Program inbox
2 to answer- Daniel Brennan“Since Tuesday there’s a red, itchy rash where I injected.”Possible side effectNeeds review
- Louis Gagnon« Est-ce que je peux parler à une infirmière en français? »To answer
- Amira SalehAsked to move her visit to FridayAnswered
- Yusuf DemirWeek 6 check-in completedDone
Messages the automatic check flags come first.
Patient review
Daniel Brennan
Enrolled Tue, Oct 13 · consent on file · first dose Thu, Oct 15
Message from Daniel
Wed, Oct 21, 9:14 a.m.“It went fine, thanks. Since Tuesday there’s a red, itchy rash where I injected. Is that normal?”
Automatic check · 9:14 a.m.
Possible side effect: “a red, itchy rash where I injected”
Every message, form and call note is checked against the program’s examples, tested before launch and after each change. It’s a second check. You decide what it is. Examples set by the program’s medical lead and Arvenna Pharma drug safety.
Your decision
You opened Daniel’s case at 9:14 a.m. Every view is logged.
- Solvara SupportSolvara SupportGLGrace LiuProgram nurse
Program inbox
1 to answer- Louis Gagnon« Est-ce que je peux parler à une infirmière en français? »To answer
- Daniel Brennan“Since Tuesday there’s a red, itchy rash where I injected.”Reported
- Amira SalehAsked to move her visit to FridayAnswered
- Yusuf DemirWeek 6 check-in completedDone
Messages the automatic check flags come first.
Patient review
Daniel Brennan
Enrolled Tue, Oct 13 · consent on file · first dose Thu, Oct 15
Message from Daniel
Wed, Oct 21, 9:14 a.m.“It went fine, thanks. Since Tuesday there’s a red, itchy rash where I injected. Is that normal?”
Automatic check · 9:14 a.m.
Possible side effect: “a red, itchy rash where I injected”
Every message, form and call note is checked against the program’s examples, tested before launch and after each change. It’s a second check. You decide what it is. Examples set by the program’s medical lead and Arvenna Pharma drug safety.
Your decision
Side-effect report
Arvenna Pharma’s own form, version 3- Reported by
- Grace Liu, program nurse
- Aware since
- Wednesday, October 21, 2026, 9:14 a.m.
- About the patient
- Initials D.B. · 42. No contact details on the form.
- Treatment
- The program’s treatment; first dose Thu, Oct 15
What happenedRed, itchy rash at the injection site since Tuesday, October 20. Reported by message on October 21.
Drug safety decides what is reportable to Health Canada. The program sends what it was told.
SimulatedDue by end of day Thu, Oct 22 · one business dayTo: Arvenna Pharma drug safety
Sent at 10:02 a.m., on time
Reference AE-2026-0418. Drug safety confirmed receipt.The record
- 9:14 a.m.Message received from Daniel Brennan
- 9:14 a.m.Possible side effect flagged by the automatic check
- 9:14 a.m.Reviewed by Grace Liu, program nurse: possible side effect
- 10:02 a.m.Report sent by Grace Liu to Arvenna Pharma drug safety (simulated), AE-2026-0418
- 10:02 a.m.Within one business day: due Thu, Oct 22. On time.
- 10:05 a.m.Reply sent by Grace Liu, program nurse
Kept for reconciliation with the drug safety database.
Reply sent at 10:05 a.m. Daniel gets a text saying there’s a new message, with no details in it.
You opened Daniel’s case at 10:05 a.m. Every view is logged.
- Solvara SupportProgram reportAPArvenna Pharma (fictional)Read only · patient services
Program-level counts
October 2026, to date
Totals only. This view never shows a name, a message or a prescriber. Counts under 5 show as “fewer than 5”, here and in exports.
Enrolled
38
of 52 patients referred this month
Enrolment to first dose
6 days
median, across 31 patients with a first dose
Check-ins completed
112
of 140 check-ins sent
Enrolled, by province
Province Enrolled Ontario 24 Quebec 9 British Columbia fewer than 5 Atlantic provinces fewer than 5 All provinces 38 About this data
- Counted from the program’s own records each night; a patient appears in a total only after they consent.
- Side-effect reports go to drug safety directly, on its own form, not through this view.
- Nothing here says which doctors prescribe, and sales teams have no access.
Synthetic program data for this preview.
Interactive product preview. The program, therapy and patient are fictional. The safety process is simulated.
Possible side effects reach the right team
Program staff review patient messages, forms and conversations. The software provides a second check by flagging possible side effects, tested against the program’s examples before launch and after changes.
Staff send reports to the manufacturer’s drug safety team on its form and within the agreed time. Drug safety determines what is reportable.
An optional AI assistant answers from content approved by the manufacturer’s medical and compliance teams, identifies itself as AI and hands over to program staff.
The program’s name and software
The app, website and messages carry the program’s name and identify the funding company. Patient records stay with the program provider in Canada; manufacturer reports use aggregate or de-identified information.
The organization holding the contract, whether manufacturer or provider, owns the custom work.
Working with your program team
Forms, messages and contact workflows use the manufacturer’s approved content. Each change is shown as a working preview and released after approval.
We plan the interface with the provider’s technology team so nurses and reimbursement specialists keep their patient record in one place. Staff can use organizational single sign-on; patients can use Google or Apple.
Screens, messages and program content come in English and French, with additional languages and right-to-left layouts available. Clinical translations follow your approval process.
The program’s nurses and reimbursement specialists answer during its service hours. Cater’s optional 24/7 human support centre can handle setup, sign-in and navigation by phone and in-app chat, in the program’s name. Care and reimbursement questions go to the program team.
caterapp.ca/for-pharma#reviewers
For drug safety, privacy and quality
- Safety reporting. The agreement sets the reporting route and timing. Flags and reports are logged for reconciliation with the safety database.
- Privacy. The care provider holds the patient records, hosted in Canada. Cater acts under a processing agreement; patients consent at enrolment and can withdraw. Program data is not used for model training. We support the privacy impact assessment, including Law 25 for Quebec patients.
- Trust and privacy centre. Under the program’s brand, patients can read about data use, hosting, service providers, security, AI, accessibility and privacy requests. We maintain the platform information for your approval.
- Program compliance. Support starts after prescribing. The app does not reward prescribers or promote the therapy to patients.
- Quality and procurement. Changes record the request, approval and release. We supply audit materials and answer the manufacturer’s and provider’s review teams. The contract can sit with either organization.
Gap The privacy and security contact’s email address.
Cost and next steps
Each program has a one-time launch fee and an annual licence. Gap the range most programs fall in, for the launch fee and for the annual licence We quote both in writing.
A conversation can start with the manufacturer or provider. Scoping brings both teams together; a confidentiality agreement can come first.